End-Of-Life-Considerations Fail To Save Lilly’s Alimta For NSCLC At NICE
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain’s NICE has rejected Eli Lilly’s Alimta for non-small-cell lung cancer, citing cost-effectiveness issues. But the US drug maker still has options to get the drug approved by the pricing watchdog.